BioSpace News Archive

BIOTRONIK is pleased to announce five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking clinical trial session by Dr. David Kandzari, US Principal Investigator, Piedmont Heart Institute, Atlanta, Georgia.

Virgin Pulse, the leading global digital-first health and wellbeing company, today announced that new data from a study of adults with prediabetes who were enrolled in VP Transform for Prediabetes were published in JMIR Diabetes.

Biomarkers are objective, quantifiable characteristics of biological processes, such as blood pressure or heart rate, that are measurable and do not define how a person feels or functions.

Protagonist Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, reported record 2021 total revenue of $439.4 million for the full year of 2021, marking a significant increase compared to $46.6 million for 2020.

GENFIT announced its cash position as of December 31, 2021 and revenues for 20211.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA (Muscular Dystrophy Association) Clinical & Scientific Conference.

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI® (risankizumab-rzaa) for the treatment of moderate to severe Crohn’s disease in patients 16 years and older.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in the “Novel Oncology Targets” panel at the Cowen 42nd Annual Health Care Conference.